reported that elevated PD-L1 levels are associated with EGFR mutations and EGFR TKIs treatment, suggesting that the combination of anti-PD-1/PD-L1, and EGFR TKIs might have synergistic effects in NSCLC therapy (80). Here, PDCD1 is linked to non-small cell lung carcinoma.